Page 14 - Pharma Companies

Drug maker Lupin inks pact to distribute, market Pegfilgrastim in Brazil

The company has entered into an exclusive distribution and marketing agreement with Biomm SA in Brazil

Australia's Woolworths makes $613 mln drugstore play, taking on Wesfarmers

The 11th-hour move from Woolworths sets the scene for a bid war between Australia's two largest retail companies

Multiple near-term concerns trigger Divi's Laboratories' headache

Pfizer's oral Covid drug, weak sales of generics, and valuations may cap upsides

Power crisis brewing in China likely to hit Indian pharma companies

Delays in consignments, rising prices of key ingredients worry industry

Germany's Boehringer, Indian pharma in legal battle over diabetes drug

The German drug maker has obtained interim injunctions against MSN Labs and Dr Reddy's Lab

M-cap of 2 demerged entities could exceed Piramal's by 10-15%: Analysts

Analysts say the demerger will make it easier for investors to value the two companies

Zydus Cadila gets USFDA nod to market depression treatment drug in US

Drug firm Zydus Cadila on Saturday said it has received approval from the US health regulator to market Vortioxetine Tablets, used to treat depression, in the American market.

Glenmark Pharma concludes study on Covid drug Favipiravir in India

Drug firm Glenmark Pharmaceuticals on Wednesday said it has successfully completed its post-marketing surveillance study on Favipiravir in India.

Work on non-Covid vaccines gives pharma firms an injection of hope

Approach drug regulator, seeking permission to conduct clinical trials

Pharma companies lead topline growth in Q1FY22: ICICI Direct Research

Corporate earnings for April-June were robust despite the second wave of Covid-19 and a report by ICICI Direct Research showed that topline growth during quarter was led by pharmaceutical companies

Serum Institute buys 50% stake in pharma packaging firm Schott Kaisha

The joint venture is for pharmaceutical packaging

4 more pharma companies to start vax production by Oct-Nov: Mandaviya

Union Health Minister Mansukh Mandaviya has said that four more Indian pharmaceutical companies may start the vaccine production by October-November to accelerate the inoculation drive.

GlaxoSmithKline Pharma Q1 net profit up 9% at Rs 121 crore

Drug firm GlaxoSmithKline Pharmaceuticals on Monday reported a 9.24 per cent rise in consolidated net profit to Rs 121.08 crore for the quarter ended June 30, 2021.

Vaccine maker BioNTech to use mRNA technology to target malaria

Pharmaceutical company BioNTech said Monday that it wants to use the mRNA technology behind its coronavirus vaccine to target malaria.

Jubilant Pharmova posts Q1 consolidated net profit of Rs 160 crore

Drug firm Jubilant Pharmova on Friday reported a consolidated net profit of Rs 160.49 crore from continuing operations for the quarter ended June 30, 2021. The company had posted a net profit of Rs 35.39 crore for the year-ago period, Jubilant Pharmova said in a regulatory filing. Revenue from continuing operations stood at Rs 1,634.65 crore in the quarter under review. It was Rs 1,156.07 crore in the same period a year ago, it added. Figures for the quarter are not comparable with previous periods since the Life Science Ingredients business was demerged with effect from February 1, 2021 pursuant to the composite scheme of arrangement during the previous year, the filing said. "During this quarter, in addition to YoY increase, we also reported sequential improvement in the specialty pharma segment with gradual recovery across radiopharmaceuticals, radiopharmacy and allergy business," Jubilant Pharmova Chairman Shyam S Bhartia and Co-Chairman & MD Hari S Bhartia said in a ...

Gland Pharma Q1 consolidated net profit up 12% to Rs 350.7 crore

Drug firm Gland Pharma on Wednesday reported an 11.83 percent increase in its consolidated net profit to Rs 350.7 crore for the quarter ended June 30, 2021, on account of robust sales in all markets.

Tatva Chintan Pharma IPO subscribed 4.51 times on first day of subscription

The initial public offer aggregating up to Rs 500 crore comprises a fresh issue of up to Rs 225 crore and an offer for sale of up to Rs 275 crore.

Abbott's Korea-imported PanBio Covid-19 self test launched at Rs 325

Firm expects demand from both, institutions and retail consumers, will import kits in 4-pack sizes from Korean plant; Test linked with NAVICA app which uploads results on ICMR website

MSN Labs enters into licence deal with DRDE for Covid-19 drug 2-DG

Drug firm MSN Laboratories on Friday said it has entered into a licence agreement with the Defence Research & Development Establishment (DRDE) for the manufacturing, distribution and marketing of 2-Deoxy-D-Glucose (2-DG), used for the treatment of COVID-19. Developed by DRDO, 2-DG has been granted permission by the Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, MSN Labs said in a statement. The company has entered into a licence agreement with DRDE and the Institute of Nuclear Medicine and Allied Sciences (INMAS) establishments of DRDO for the manufacturing, distribution and marketing of 2-Deoxy-D-Glucose (2-DG) in India, it added. MSN labs will be launching the 2-DG as a twice-a-day product in sachet form under the brand name MSN 2D in strength of 2.34 g, the statement said.

Covid-19 crisis: Sputnik V, Moderna vaccines work against Delta variant

The protective proteins are called neutralizing antibodies because they're capable of preventing the virus from entering cells